Short‐, mid‐, and long‐term effects of a polymer‐free tacrolimus‐eluting stent in a porcine coronary model
Source abstract
Abstract
Abstract Stent‐based delivery of tacrolimus has shown neointimal hyperplasia and restenosis reduction; FK506 is a water insoluble macrolide immunosuppressant. The purpose of this study was to evaluate acute and chronic tissue response to a polymer‐free FK506 drug‐eluting stent implantation in a porcine coronary artery model. Seventy‐eight nonatherosclerotic minipigs underwent successful placement of 134 stents (control n = 56; FK506 (1.5 μg/mm2) n = 44; FK506 (2.6 μg/mm2) n = 34) at 7, 15, 30, 90, or 180 days. Endothelialisation was almost complete at 7 days, complete at 15 days. At 30 and 90 days, mean neointimal thickness, neointimal area, and % stenosis was significantly less for drug‐eluting stents compared with controls. At 180 days, histomorphometric values were similar for eluting and control stents. The FK506‐eluting stent allows for a complete re‐endothelialisation at 15 days and favorably moderate neointimal hyperplasia at 30 and 90 days in the porcine coronary model. Because of a possible limited bioavailability of FK506, long‐term inhibition of neointimal formation was not sustained at the considered follow‐up. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Cardiac Valve Diseases and Treatments · Cardiac and Coronary Surgery Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (24)
Show source-provided references
1. 10.1056/NEJM19981203339230410.1056/NEJM199812033392304 ↗
2. 10.1056/NEJM19940825331080110.1056/NEJM199408253310801 ↗
3. 10.1016/0735-1097(92)90119-810.1016/0735-1097(92)90119-8 ↗
4. 10.1016/S0735-1097(97)00450-610.1016/S0735-1097(97)00450-6 ↗
5. 10.1161/01.CIR.0000050367.65079.7110.1161/01.CIR.0000050367.65079.71 ↗
6. 10.1161/hc3601.09398710.1161/hc3601.093987 ↗
7. 10.1002/ccd.1066410.1002/ccd.10664 ↗
8. 10.1016/j.cardiores.2004.04.02910.1016/j.cardiores.2004.04.029 ↗
9. 10.1002/ccd.2021310.1002/ccd.20213 ↗
10. 10.1016/j.cardiores.2004.06.01610.1016/j.cardiores.2004.06.016 ↗
11. 10.1097/01.RVI.0000082982.70522.5D10.1097/01.RVI.0000082982.70522.5D ↗
12. 10.1007/s10856-005-4733-410.1007/s10856-005-4733-4 ↗
13. 10.2460/javma.2001.218.66910.2460/javma.2001.218.669 ↗
14. 10.1016/0735-1097(94)90126-010.1016/0735-1097(94)90126-0 ↗
15. 10.3109/1052029860911070810.3109/10520298609110708 ↗
16. 10.1016/0735-1097(92)90476-410.1016/0735-1097(92)90476-4 ↗
17. 10.1056/NEJM19910103324010310.1056/NEJM199101033240103 ↗
18. 10.1007/s00270-001-1729-410.1007/s00270-001-1729-4 ↗
19. 10.1161/01.CIR.0000033973.06059.0410.1161/01.CIR.0000033973.06059.04 ↗
20. Use of a tacrolimus‐eluting stent to inhibit neointimal hyperplasia in a porcine coronary model
21. 10.1097/01.fjc.0000248233.22570.8b10.1097/01.fjc.0000248233.22570.8b ↗
22. 10.1161/01.CIR.94.7.169010.1161/01.CIR.94.7.1690 ↗
23. 10.1016/0021-9150(94)05472-U10.1016/0021-9150(94)05472-U ↗
24. 10.1046/j.1540-8183.2003.01050.x10.1046/j.1540-8183.2003.01050.x ↗